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Abstract
Genetic and biochemical studies were carried out in 96 rela-
tives of six independently ascertained probands with familial
dysbetalipoproteinemia (FD) carrying the APOE *2
(Lysl46-+Gln) allele. Compared to noncarriers, the 40 het-
erozygous APOE*2(Lysl46-+G1n) allele carriers exhibited
markedly increased mean levels of cholesterol and triglycer-
ide in the very low density lipoproteins (VLDL) (1.89+0.37
vs 0.30±0.27 and 1.86±0.37 vs 0.68±0.27 mmol/liter,
respectively) and plasma apolipoprotein (apo)E levels
(28.1+1.6 vs 4.6±1.1 mg/dl), which is characteristic for FD.
By means of a pedigree-based maximum likelihood
method we calculated that carrier-status accounted for 57%
and 71%, respectively, of the total variance of the ratio
(VLDL + IDL)-cholesterol/plasma triglyceride and plasma
apoE levels.
APOE*2(Lys146-+Gln) and APOE*3-Leiden allele car-
riers were found to differ significantly in: (a) plasma apoE
levels, (b) in the amounts of triglycerides in the VLDL and
VLDL + IDL fraction, and (c) in the amount of cholesterol
in the VLDL and VLDL + IDL fraction relative to the
amount of triglyceride in these fractions. In the APOE*2
(Lysl46-+Gln) allele carriers the VLDL and VLDL + IDL
fraction is relatively rich in triglycerides as compared with
that in APOE*3-Leiden carriers. We hypothesize that these
two rare mutations of apoE both lead to dominantly inher-
ited forms of FD along different underlying metabolic de-
fects. (J. Clin. Invest. 1994.94:1252-1262.) Key words: dom-
inant mode of inheritance * family studies - apoE3-Leiden
* type m hyperlipoproteinemia
Introduction
Apolipoprotein E (apoE) is one of the major protein constit-
uents of chylomicron and very low density lipoprotein (VLDL)
remnants, and serves as a ligand for the receptor-mediated up-
take of these lipoprotein particles by hepatic lipoprotein recep-
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ratory, P.O. Box 430, 2300 AK Leiden, The Netherlands.
Receivedfor publication 28 June 1993 and in revisedform 13 March
1994.
tors (1, 2). Defects in apoE may lead to an impaired clearance
of these particles from the blood stream (3), and, as a conse-
quence, plasma levels of cholesterol, triglycerides, and apoE
are elevated (familial dysbetalipoproteinemia, FD)' (4). In FD
patients the chylomicron and VLDL remnant particles (,6-
VLDL) are enriched in cholesterol, leading to a strong predispo-
sition for coronary and/or peripheral artery disease in these
patients. Clinical abnormalities like palmar xanthomas and tu-
bero-eruptive xanthomas are present in approximately 50% of
the patients at the time of initial diagnosis (4).
Three common genetic variants of apoE were originally
identified by isoelectric focusing and designated apoE2, apoE3,
and apoE4 (5, 6). Molecular characterization showed that the
apoE2 and apoE4 isoforms were encoded by APOE *2
(Argl58-+Cys) and APOE*4(Cysl 2--Arg) alleles, each dif-
fering from the wild type APOE*3 allele by single point muta-
tions at codons 158 and 112, respectively (7-10). Homozygos-
ity for the APOE*2(Argl58-+Cys) allele is present in the vast
majority of patients with FD. However, in caucasian populations
only 1 to 4% of all APOE*2(Argl58-+Cys) homozygotes de-
velop hyperlipoproteinemia. This suggests that additional ge-
netic and/or environmental factors are required for its manifes-
tation (11, 12).
A number of studies demonstrated that the domain of apoE
between amino acids 131-150 is responsible for the high affin-
ity binding to the LDL receptor ( 13-16). This receptor binding
is suggested to occur by the direct ionic binding of some of the
positively charged amino acid residues in the binding domain
of apoE with negatively charged amino acid residues in the
ligand binding domain of the LDL receptor. Heterozygosity for
apoE variants with mutations removing a positively charged
amino acid in the binding domain have been described in
patients with FD: apoE3(Cysl 12-+Arg;Argl42--Cys) (17,
18), apoEl-Harrisburg(Lysl46--KGlu) (19, 20), apoE4-Phila-
delphia(Glul3-'Lys;Argl45-4Cys) (21, 22), apoE2-Christ-
church(Argl36-'Ser) (23, 24), and apoE2(Argl45-'Cys) (24,
25). For some of these apoE variants, i.e., apoE3(Cysil2-+
Arg; Argl42-+Cys), apoEl -Harrisburg (Lys146-+Glu), and
apoE4-Philadelphia( Glu 1 3-Lys; Argl45-*Cys), association
with a dominant inheritance pattern of FD has been reported
(18-20, 22).
In patients of Dutch descent two additional apoE variants
have been found with dominant association of FD: apoE2
(Lysl46-KGln) (26, 27) and apoE3-Leiden (28-32). The
1. Abbreviations used in this paper: BMI, body mass index; FD, familial
dysbetalipoproteinemia; LPL, lipoprotein lipase.
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apoE2(Lys146--Gln) variant was first described by Rail et
al. (33).
In a previous paper, we described the dominant inheritance
of FD in APOE*3-Leiden carriers of a large multigeneration
family (32). Because a large number of gene carriers could be
studied, we were able to perform statistical analyses of the
expression of FD in the APOE*3-Leiden allele carriers (32). In
this study, the identification of eight probands and their family
members allowed us to carry out a similar study with APOE *2
(Lysl46-{Gln) allele carriers. We performed an extensive fam-
ily study on six pedigrees of FD probands with the APOE*2
(Lysl46-*Gln) allele, who probably share common ancestry.
Lipid and lipoprotein analyses revealed a strong association of
the APOE*2(Lysl46-{Gln) allele with FD, most likely caused
by an impaired conversion of VLDL into IDL. Comparison of
the present results with those obtained in our previous apoE3-
Leiden family study (32), implies that both of these two rare
mutations in the APOE gene cause dominantly inherited forms
of FD but along different underlying metabolic defects.
Methods
Subjects. Through the screening of hyperlipidemic patients for biochemi-
cal and genetic parameters a total number of eight, independently ascer-
tained, FD probands were identified exhibiting heterozygosity for the
rare APOE*2(Lysl46-+Gln) allele. Probands M.N., F.D., and F.V. have
previously been described by Smit et al. (26, 27), and were originally
identified in the Lipid Clinic in Leiden. Later, proband F.H. was also
identified among the Leiden patients. Probands R.v.D. and A.B. were
identified as FD patients in the Lipid Clinic in Nijmegen. Proband R.L.
was identified in the Lipid Clinic in Amsterdam. M.d.H. was identified
in Cape Town, South Africa, after having an acute myocardial infarction.
He is of Belgian desent, and was born close to the Dutch-Belgian border.
EDTA blood samples were collected after overnight fasting. Plasma
was separated from cells by centrifugation at 500 g for 10 min at room
temperature, and was used for lipid and lipoprotein analysis. Secondary
causes of hyperlipidemia were excluded by standard laboratory tests. Geno-
mic DNA was isolated from leukocytes using standard procedures (34).
APOE genotyping. APOE genotyping of the common polymor-
phisms at codons 112 and 158 was performed by polymerase chain
reaction (PCR) of the region encompassing both polymorphic sites,
digestion of the PCR products with restriction enzyme HhaI and electro-
phoresis on polyacrylamide gel as described earlier (30, 32, 35).
Detection of the APOE *2 (LysJ46-+Gln) mutation. Identification of
APOE*2(Lysl46-+Gln) allele carriers was performed by PCR using a
mutagenic amplification primer assay (Fig. 1). Primer 3012 5' GGC-
ATCGCGGAGGAGAGCAGCT-3' (nucleotides 3848-3867, non-cod-
ing strand) was designed with a nucleotide mismatch (underlined) as
compared to the wild type APOE sequence (36). In the case of the
APOE*2(Lysl46-+Gln) allele a PvuII restriction site is introduced due
to a base pair substitution specific for this allele and the nucleo-
tide mismatch in the primer. PCR was performed using this primer
and primer 398 5 '-GCGGGCACGGCTGTCCAAGG-3' (nucleotides
3678-3697, coding strand). The reaction mixture included 50 pmol
of each primer, 0.5 Mg genomic DNA, 0.2 mM deoxyribonucleotide
triphosphates (dNTPs), 0.5 mM MgCl2, 50 mM KCl, 10 mM Tris-
HC1 pH 8.3, 200 tzg/ml BSA, 0.1 U of Taq polymerase (superTaq)
(Boehringer Mannheim GmbH, Mannheim, Germany) and 10% dimeth-
ylsulphoxide (vol/vol) in a total volume of 50 jul. Amplification was
performed for 32 cyci of 1 min at 95°C, 30 s at 55°C, and 1 min 30 s
at 72°C, with an initial denaturation period of 4 min. Some 15 pII of
PCR products were digested with restriction enzyme Pvull according
to recommendations of the supplier (Pharmacia Fine Chemicals, Piscata-
way, NJ). Thereafter, fragments were separated on a neutral 7.5% poly-
acrylamide gel, stained with ethidium bromide, and photographed on a
UV source. Digestion of the PCR product of a heterozygous APOE *2
(Lysl46-+Gln) carrier with Pvull, will result in patterns consisting of
three fragments: an undigested fragment of 189 bp, originating from
the normal allele, and 171-bp and 18-bp fragments, originating from
the mutant allele. The 18-bp fragment is not visible in Fig. 1.
Haplotyping ofAPOE*2(Lys146-+Gln) alleles. Genomic DNA ob-
tained from informative family members in branches of all six pedigrees
was used for Southern blot analysis. Seven different restriction fragment
length polymorphisms (RFLPs) in the APOE-C1-C2 gene cluster were
tested (37-39). For analysis of the polymorphic HpaI-site, located in
the promoter region of the APOC1 gene (40), PCR was performed
according to Nillesen et al. (41). Subsequently, PCR products were
digested using restriction enzyme Hincd, which reveals the same poly-
morphism. In addition, the (TG)n(AG)m microsatellite marker in the
first intron of APOC2 was analyzed by PCR, using primer set Mfd5CA/
MfdGT (42, 43).
Genealogical studies. Genealogical studies were carried out using
information obtained from different sources: interviews with family
members, parish archives from the 17th and 18th centuries and local
civil registration, population, and census records from the 19th and 20th
centuries.
Lipid and lipoprotein analysis. For the isolation of VLDL + IDL
(d < 1.019 g/ml), 2 ml of plasma was brought to a density of 1.019
g/ml with potassium bromide and overlayered with a 3.5-ml solution
of sodium chloride (d = 1.019 g/ml) in a 10.4-ml centrifuge tube fitting
the 50 Ti fixed-angle rotor (Beckman Instruments, Geneva, Switzer-
land). VLDL + IDL was aspirated from the top (1 ml fraction) after
centrifugation at 106,000 g for 16 h at 40C. For the isolation of VLDL
(d < 1.006 g/ml), 2 ml of plasma was overlayered with a 2.5-ml
solution of NaCl (d = 1.006 g/ml) in a 5-ml tube fitting the 40 Ti
swing-out rotor (Beckman Instruments). VLDL was aspirated from the
top (1 ml fraction) after centrifugation at 90,000 g for 16 h at 40C.
High density lipoprotein (HDL) was determined in the infranatant after
precipitation of IDL and LDL (44).
Plasma and lipoprotein cholesterol concentrations in VLDL (d
< 1.006), VLDL + IDL (d < 1.019), and HDL fractions were mea-
sured using the CHOD-PAP kit (No. 236691; Boehringer Mannheim
GmbH). Plasma and lipoprotein triglycerides were measured using the
GPO-PAP kit (No. 701904; Boehringer Mannheim GmbH). IDL-cho-
lesterol was calculated as the difference between VLDL + IDL-choles-
terol (d < 1.019 g/ml) minus VLDL-cholesterol (d < 1.006 g/ml).
LDL-cholesterol (1.019 < d < 1.063 g/ml) was calculated using the
formula: LDL-cholesterol = plasma-cholesterol - (VLDL-cholesterol
+ IDL-cholesterol + HDL-cholesterol).
Agarose electrophoresis for the detection of 63-VLDL was performed
as described by Demacker et al. (45).
ApoE quantification. ApoE concentrations were measured by sand-
wich ELISA. Affinity purified polyclonal goat anti-human apoE antibod-
ies were used for coating. Affinity purified polyclonal rabbit anti-human
apoE antibodies were used as second antibodies. As second antibody
swine anti-rabbit IgG antibodies conjugated to horseradish peroxidase
were used. Color development was performed using tetramethylbenzi-
dine. Pool plasma with known apoE level and obtained from healthy
individuals was used as a standard.
Statistics. For the statistical analyses we considered allele carriers
and noncarriers of six different families, implying that, in a strict sense,
there were only six independent observations. Therefore, to test for the
statistical significance of the effect of the mutant APOE*2
(Lysl46-Gln) allele on the lipoprotein traits in these six families, we
used a pedigree-based maximum likelihood method developed by Lange
et al. (46), in which for a given pedigree of n individuals a vector of
observations (x) is defined and a vector of expected values [E(x)],
that can depend on measured variables such as sex or measured geno-
type. The covariances between the residual part of the observations, i.e.,
the part that is not accounted for by the measured genotype, depend on
the relationships between the pedigree members and on the genetic
model assumed for the observations. Throughout we have modeled the
variances not accounted for by the measured genotype as consisting of
additive genetic and random environmental variance, recognizing that
ApoE2(Lys 146-Gln) Associated with Familial Dysbetalipoproteinemia 1253
Table I. Clinical Characteristics of the APOE*2(LysJ46-.Gln) Probands at the Time Point of Diagnosis
Probands with the APOE*2(Lysl46*Gln) allele
M.N. F.D. F.V.* R.L. F.H. R.v.D.1 A.B. M.d.H.
Age 41 31 36 40 66 48 41 58
Gender F M M M M F M M
Plasma cholesterol (mmol/liter) 18.4 13.9 39.3 12.9 12.4 8.0 7.1 9.3
Plasma triglycerides (mmollliter) 17.9 5.3 33.3 8.3 3.5 2.7 3.7 3.6
VLDL-cholesterollplasma triglycerides
(mmollmmol) 2.111 2.0911 1.5011 0.78 1.15 1.06 0.71 N.D.
fl-VLDL1 + + + + + + + +
Second APOE allele E*3 E*3 E*3 E*2 E*3 E*4 E*3 E*4
Clinical signs** + + + + + + + +
Plasma samples were collected after an overnight fasting. N.D.: not determined. * Proband F.V. was very overweight at timepoint of sampling.
* Proband R.v.D. was following dietary guidelines. § Proband A.B. was under medication (gemfibrozil). 11 Ratio cholesterol/triglycerides (mmol/
mmol) was measured in VLDL after centrifugation of for 30' at 30,000 g at d < 1.006 to remove chylomicrons. I Presence (+) of 63-VLDL, as
revealed by agarose electrophoresis of VLDL d < 1.006 g/mL fraction.
vascular disease.
the genetic part may also reflect environmental influences shared by
family members. However, our main interest is to test for the influence
of the measured genotype, and not to explain the remaining variance.
For a given E(x) and expected covariance matrix 1, the log likelihood
of obtaining the observation vector x is: L = -1/21nlnl - 1/2[x
- E(x) ]'I -'[x - E(x)] + constant; where ' denotes matrix transpose.
The joint log-likelihood of obtaining all pedigrees is the sum of the
log-likelihood of the separate pedigrees. Estimation involves selection of
parameter values under a specific model that maximizes the joint likeli-
hood of all pedigrees. The likelihoods obtained for different models can
be compared with chi-squared difference tests where x2 = 2(L, - LO)
and LI and Lo denote the log likelihood for the general (HI) and the
constrained (HO) hypothesis. The degrees of freedom (df) for this test
are equal to the number of independent parameters between HI and Ho.
(47). The Fisher package (46) was used for genetic modeling. Ascertain-
ment correction was carried out by conditioning on the probands.
To test for the difference between the APOE*2(Lysl46-Gln) and
APOE *3-Leiden allele with respect to their effect on plasma lipoprotein
levels, a nested multivariate analysis of variance (MANOVA) was per-
formed, with individuals nested within families. Data from the probands
of each pedigree were discarded. Also, one pedigree with only one
carrier for the APOE*2(Lys146-<Gln) mutation in addition to the pro-
band was omitted from the analysis. To test which individual lipid traits
are responsible for the difference between both groups, a univariate
analysis of variance (ANOVA) was used.
Results
** Presence of xanthomas and/or coronary artery disease/peripheral
after cysteamine treatment of plasma (results not shown). Simi-
lar incomplete modification patterns have been found earlier for
probands M.N., F.D., and F.V. (26). Definite identification of
the APOE*2(Lysl46-*Gln) mutation in these probands was
confirmed by PCR followed by PvuII digestion (Fig. 1).
Genealogical investigations and haplotype analyses. Family
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Probands. Eight independently ascertained probands, heterozy-
gous for the APOE*2(Lysl46-+Gln) allele, were identified
among FD patients attending different Lipid Clinics as indicated
in Methods. In Table I clinical and lipoprotein parameters are
shown for the probands at their first visit, unless indicated other-
wise. Three of these probands (M.N., F.D., and F.V.) have been
described before (26, 27). All probands showed clinical signs
of FD, including tuberoeruptive xanthomas, palmar streaks, or
coronary and/or peripheral vascular disease. ApoE phenotyping
and genotyping revealed that five probands carry the common
APOE *3 allele as second allele. Two probands carry the APOE-
*4(Cysl 12-+Arg) allele, whereas one proband carries the
APOE*2(Argl58-*Cys) allele. In all probands the apoE pheno-
type is changed into the E4/E3 instead of the E4/E4 phenotype
189 bp
171 bp
Figure 1. Analysis of APOE*2(Lysl46-+Gln) carriers by PCR using a
mutagenic amplification primer. (A) A relevant part of the wildtype and
mutant APOE sequence is shown. The mutated codon 146 is indicated
by a box. By PCR using a mutagenic primer an additional mutation is
introduced (underlined T), thereby resulting in a PvuH restriction en-
zyme cutting site in the mutant PCR product. (B) 2% agarose gel
electrophoresis of PCR products using amplification primers 398 and
3012 after Pvull restriction enzyme digestion. The lanes represent pro-
bands MN, FD, FV, RL, FH, RvD, and AB. Two healthy APOE*3/
APOE*2(Argl58-Cys) heterozygotes were loaded as controls (C).
Proband M.d. H. gave identical bands but is not shown in the figure.
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studies could be performed for six out of eight probands, yield-
ing 96 individuals. Heterozygosity for the APOE *2
(Lysl46-*Gln) allele was observed in 40 family members. Fam-
ily pedigrees are presented in Fig. 2.
Since most of the probands originate from the southwestern
part of the Netherlands, we investigated whether common an-
cestry could be demonstrated. So far, genealogical studies re-
vealed a common ancestry only for probands M.N. and R.L.
This ancestor (in the 10th generation) was born in the early
17th century in the southwestern part of the Netherlands.
Extended haplotypes were constructed of the APOE-C1-C2
gene cluster for all pedigrees, using restriction enzymes HpaI,
DraI, BglI, NcoI, BamHI, Avail, BanI, and TaqI. We found that
in all six pedigrees shown in Fig. 2, the APOE*2(Lysl46--Gln)
mutation cosegregated with one unique haplotype that occurred
only twice among eighteen unrelated non-carrier haplotypes.
This unique haplotype is designated HpaIl, DraI2, BglI2,
NcoIl, BamHI2, Availl, BanI2 and TaqI2, whereby 1 and 2
stand for absence and presence of cutting site, respectively.
Additional evidence for the presence of a unique APOE*2
(Lysl46-KGln) allele in all pedigrees was obtained by including
the (TG)n(AG)m microsatellite marker in intron 1 of APOC2
(43). In all 40 APOE*2(Lysl46-+Gln) allele carriers, a frag-
Figure 2. Pedigrees of 6 out of 8 probands. The probands are indicated by an arrow.
Roman numbers represent successive generations. The numbering corresponds with that
in the appendix. Female and male carriers of the APOE*2(Lys146-Gln) are indicated
by half filled circles and boxes, respectively. Open and closed symbols represent noncar-
riers and carriers, respectively. Individuals marked by a dot could not be studied.
ment of 149 bp (designated allele G7) was observed, whereas
this allele was not detected in any of the 56 noncarriers. In a
caucasian population this allele was found to have a very low
frequency of about 3% (43).
Lipid and lipoprotein levels in carriers versus non-carriers.
Plasma samples of six probands and the 96 additional family
members were studied for lipid and lipoprotein parameters (see
Appendix for individual data). To avoid possible ascertainment
bias, in all statistical calculations the data of the probands were
excluded. The descriptive statistics of allele carrying (n = 40)
and noncarrying (n = 56) family members are presented in
Table II. As expected for subjects with FD characteristics, the
mean levels are elevated for all lipid traits except for LDL and
HDL cholesterol. Compared to noncarriers, the APOE *2
(Lysl46-*Gln) allele carriers exhibited markedly increased
mean levels of cholesterol and triglyceride in the very low
density lipoproteins (VLDL) (1.89±0.37 vs 0.30±0.27 and
1.86±0.37 vs 0.68±0.27 mmol/liter, respectively) and plasma
apolipoprotein (apo)E levels (28.1±1.6 vs 4.6±1.1 mg/dl),
characteristic for FD. Strikingly, the mean intermediate density
lipoprotein (IDL)-cholesterol level was only slightly elevated
in carriers (0.54±0.03 vs 0.29±0.03 mmol/liter). Also the
mean ratio (VLDL + IDL)-cholesterol/plasma triglyceride is
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Table II. Descriptive Statistics (means±standard errors)
of the APOE*2(LysJ46-+Gln) Allele Carriers
and Their Non-carrier Relatives
APOE*2(Lysl46-Gln) Non-carrier
allele carriers relatives
(n = 40) (n = 56)
BMI* 23.3±0.8 24.9±0.6
Plasma TG 2.69±0.42 1.31±0.30
VLDL-TG 1.86±0.37 0.68+0.27
Plasma Chol 6.68±0.36 5.94±0.29
VLDL-Chol 1.89±0.37 0.30±0.27
IDL-Chol 0.54±0.03 0.29±0.03
LDL-Chol 2.74±0.65 3.03±+0.18
HDL-Chol 1.37±0.07 1.53+0.05
(VLDL + IDL)-Chol/Plasma TG 0.85±0.03 0.50±0.02
ApoE 28.1±1.6 4.6±1.1
Means and asymptotic standard errors were estimated from "best-fit"
models using the maximum likelihood estimate procedures implemented
in the Fisher program. Probands were excluded for these quantitative
analyses. * All levels are expressed as mmol/liter, except BMI (kg/
mi2) and apoE (mg/100 ml).
strongly elevated. The statistical analyses of these results are
presented in Table III.
We considered allele carriers and noncarriers of six different
families, implying that, in a strict sense, there were only six
independent observations. Therefore, to test for the effect of
the mutant APOE*2(Lysl46--+Gln) allele in these six families,
we used a pedigree-based maximum likelihood method devel-
oped by Lange et al. (46). The principles of this method of
statistical analyses are briefly described in Methods. The statisti-
cal analyses of the lipoprotein levels (Table II) are shown in
Table III as log-likelihood estimates for six models (as indicated
in the legends of Table III). In this table we also present,
when significant, the percentage of the total variance that can
be explained by gender and carrier status, respectively. It is
obvious that gender significantly influences levels of plasma and
VLDL triglyceride, as well as VLDL, IDL, and HDL cholesterol
concentrations. Gender explains 12.1 % of the total variance of
HDL cholesterol levels.
From Table HI we also conclude that carrying the APOE*2
(Lysl46-<Gln) allele does significantly affect plasma levels of
plasma triglyceride and all lipoprotein levels considered, but not
the level of total plasma cholesterol. It is also apparent from this
table that the carrier status explains the total variance of these
traits for about 25 to 35%. As expected, carrier status is responsible
for 57% of the variance in the ratio (VLDL + IDL)-cholesterol/
plasma triglyceride, whereas 71% of the total variance of the apoE
level is explained by the carrier status. In addition, Table III shows
that all traits, except plasma-, IDL-, and LDL-cholesterol, are also
influenced by additional genetic factors.
An increased ratio of (VLDL + IDL)-cholesterol/plasma
triglyceride indicates the presence of /3-migrating VLDL parti-
cles. Like in the APOE*2(Lysl46-KGln) carrying FD probands,
the presence of /-migrating VLDL particles was also clearly
Table III. Results of Maximum Likelihood Analyses on the Quantitative Traits and BMI in the ApoE2(LysJ46-+Gln) Pedigrees
Percent variance
explained by
Best Total Carrier
A B C D E F model variance Gender status
Df for difference test 1 2 3 1 1
BMI -167.97 -168.01 -168.69 -170.85 -172.09 -181.15* E 16.0
Plasma TG -93.55 -96.48* -94.09 -94.26 -101.32* -103.72* D 3.88 3.8 25.5
VLDL-TG -81.09 -84.92* -81.56 -81.77 -88.35* -92.37* D 3.06 4.9 26.1
Plasma Chol -113.40 -113.80 -114.12 -116.33 -118.03 -118.53 F 4.33
VLDL-Chol -91.55 -93.66* -91.69 -91.80 -101.49* -95.13* D 3.46 2.6 24.4
IDL-Chol 127.44 125.35* 127.09 126.33 107.26* 126.33 D/F 0.04 2.8 36.4
LDL-Chol -37.33 -37.35 -37.94 -39.39 -52.16* -41.24 F 1.30 33.2
HDL-Chol 81.78 72.72* 81.72 79.51 75.38* 71.22* D 0.11 12.1 25.6
(VLDL + IDL)-Chol/Plasma TG 136.30 136.07 135.13 133.77 92.67* 133.46 F 0.05 56.9
ApoE -236.60 -237.82 -238.68 -238.98 -294.29* -241.36* D 196 71.3
Log-likelihood estimates for six models and, when significant, the percent of total variance explained by gender and carrier-status are shown.
* indicates a significant deterioration of a model when compared with the preceding best fitting one. Model definition: A, Most general model
allowing for: (i) differences in mean values for the 7 different genotypes, (ii) gender-difference, (iii) an additive genetic influence, and (iv) random
environmental variability; B, No gender difference; C, All carriers have the same means; D, All noncarriers have the same means; E, No difference
between carriers and noncarriers; F, No additive genetic variance allowed. Testing procedure: (1), Model B is tested against model A. When twice
the difference in log-likelihoods of these models is higher than the x2 corresponding to df = 1 and P = 0.05 (3.84) than this indicates a significant
gender difference. (2) Model C (with df = 2) is tested against model B as described above. When model B was significantly different from model
A, then model C was tested against model A. (3) Model D (with df = 3) is tested against model C. When model C differs significantly from model
B than D is tested against model B. (4) Model E (with df = 1) is tested against model D or, in case of a significant deterioration of model D,
against model C. (5) Model F (with df = 1) is tested against model E or, in case of a significant deterioration of model E, against model D. The
best model is the most parsimonous model: e.g., for plasma triglycerides this is model D, with significant deteriorations in models B, E, and F.
This shows that there are (i) significant differences between the carriers and noncarriers; (ii) significant gender differences; (iii) significant additive
genetic variability (by genes other than APOE); and (iv) there is no variability between the carriers and between the noncarriers.
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Table IV. Differences between APOE*2(Lysl46--+Gln)
and APOE*3-Leiden Allele Carriers: Results
of Nested Univariate ANOVA
apoE2(Lysl46-Gln) apoE3-Leiden Combined Univariate
(n = 39) (n = 37) (n = 76) ANOVA
Plasma TG 3.23±2.64 2.19±0.83 2.75±2.03 0.009
VLDL-TG 2.37±2.36 1.17±0.65 1.82±1.84 0.001
Plasma Chol 6.70±2.90 7.10±2.12 6.91±2.55 0.981
VLDL-Chol 2.29±2.58 1.56±1.08 1.98±2.03 0.039
HDL-Chol 1.24±0.21 1.34±0.33 1.28±0.28 0.054
(VLDL + IDL)-Chol/
Plasma-TG 0.86±0.21 1.28±0.33 1.06±0.34 0.000
ApoE 28.9±11.6 22.8±7.8 26.0±10.4 0.004
(VLDL + IDL)-Chol 2.80±2.64 2.96±1.75 2.88±2.25 0.692
(VLDL + IDL)-TG 2.53±2.46 1.57±0.81 2.05±1.90 0.003
VLDL-Chol/Plasma-TG 0.66±0.18 0.66±0.23 0.66±0.21 0.789
(VLDL + IDL)-Chol/
(VLDL + IDL)-TG 1.22±0.36 1.89±0.45 1.56±0.53 0.000
VLDL-ChoINLDL-TG 1.00±0.27 1.29±0.32 1.14±0.33 0.000
Probands were excluded from these analyses. Nested univariate ANOVA was
used to estimate the significance of the difference between the two carrier groups.
detectable in the 36 other carriers, whereas only in four APOE *-
2(Lysl46-Gln) allele carriers the presence of these particles
was less evident (see Appendix). From the results presented in
Tables II and Ill, we conclude that most plasma lipid and lipo-
protein parameters characteristic for FD were significantly ele-
vated in the group of carriers when compared with the group
of noncarriers.
Comparison between APOE *2(LysJ46-Gln) and
APOE *3-Leiden allele carriers. The unique availability of two
large groups of carriers either of the APOE*2(Lysl46-+Gln)
allele described in this study and the APOE*3-Leiden allele
(32), enabled us to compare the specific effects of these two
rare apoE mutations on the expression patterns of FD. As in
both groups the carriers are not unrelated (family members of
six and five different families, respectively), statistically sig-
nificant differences in lipoprotein traits between these two
groups of carriers were analyzed using a nested multivariate
analysis of variance (MANOVA), with individuals nested
within families and excluding the respective probands. With
this analysis, we found that the APOE*2(Lysl46-.Gln) allele
carriers differ significantly from the APOE *3-Leiden allele car-
riers considering the lipoprotein traits presented in Table IV (P
< 0.001). Nested univariate ANOVA of these lipid traits re-
vealed that the statistically significant differences between
APOE*2(Lysl46-.Gln) and APOE*3-Leiden allele carriers
are due to differences in: (a) plasma apoE levels, (b) in the
amounts of triglycerides in the VLDL and VLDL + IDL frac-
tion, and (c) in the amount of cholesterol in the VLDL and
VLDL + IDL fraction relative to the amount of triglyceride in
these fractions (cholesterol/triglyceride ratios). From Table IV
we conclude that in the APOE*2(Lysl46-.Gln) allele carriers
the VLDL and VLDL + IDL fraction is relatively rich in triglyc-
erides as compared with that in APOE *3-Leiden allele carriers.
Discussion
In general, FD is associated with homozygosity for the
APOE*2(Argl58-*Cys) allele and is manifested as a reces-
sively inherited multifactorial disease, i.e., additional factors,
genetic and/or environmental, are needed for its expression.
For these "classical" FD patients age, nutritional status, obe-
sity, and gender are important factors in the expression of the
disease (4).
Next to the recessive form of FD, rare apoE variants exist
for which heterozygosity is associated with the expression of
FD. These variants include apoE3 (Cysi l2-+Arg;Arg142-+
Cys), apoE1-Harrisburg(Lys146--Glu), apoE4-Philadelphia
(Glul3-Lys;Argl45-.Cys), and apoE3-Leiden (18, 19, 22,
32). Thus far, all family members showing heterozygosity for
one of these rare mutant forms of apoE had more or less severe
hyperlipidemia. Thus for these variants, FD is inherited in a
dominant fashion with a high penetrance, although with variable
expression.
In 1983 Rall et al. (33) reported heterozygosity for the
APOE*2(Lysl46-+Gln) allele in two unrelated males with FD.
Later, we reported three independently ascertained Dutch fami-
lies in which heterozygosity for the APOE*2(Lysl46-*Gln)
allele appeared to be associated with the expression of FD (26,
27). Although in these studies evidence was obtained for a
dominant mode of inheritance of FD, the number of APOE*2
(Lysl46-*Gln) allele carriers was too low to study the expres-
sion of FD in these carriers by statistical analyses, like we have
been able to carry out for the extended multigeneration apoE3-
Leiden family (32). However, recent screening of FD patients
for the presence of the APOE*2(Lysl46--+Gln) allele resulted
in the identification of five additional index patients (Table I).
From six pedigrees together, we were able to identify 40
additional APOE*2(Lysl46-KGln) allele carriers among a total
of 96 first degree relatives. Haplotype analysis of the APOE-CI-
C2 gene cluster in these six families revealed a unique haplotype
cosegregating with the APOE*2(Lysl46-+Gln) allele and thus
pointing to common ancestry. Preliminary analysis suggested
that one of the remaining two probands did not carry the same
haplotype, indicating that the APOE*2(Lysl46-+Gln) mutation
may be a recurrent mutation. Of the apoE2(Lysl46-*Gln) FD
patients described by Rall et al. (33) haplotyping was not possi-
ble as additional family material was not available. At present,
we have preliminary data that at least three additional unrelated
hyperlipidemic patients carrying the APOE*2(Lysl46-*Gln)
allele do exist among Dutch FD patients. Taken the FD popula-
tions of all the three lipid clinics together, about 8% of all index
cases were heterozygous carriers of the APOE*2(Lys-
146-{Gln) allele.
A relatively large number of 40 allele carriers (excluding
the probands) allowed us now to perform statistical analyses
regarding the expression of FD. Moreover, it enabled us to
compare the effect of the APOE*2(Lys146-*Gln) allele on the
expression of FD with that of our previously reported APOE *3-
Leiden allele (32) and to evaluate as to whether different under-
lying metabolic defects are involved.
Previously, to analyze the effect of the dominant APOE*3-
Leiden allele on the expression of FD by investigating family
members of the different probands, we used the conventional
statistical analyses of Mann-Whitney rank sum test and multi-
ple regression analyses after logaritmic transformation of the
dependent variables (32). However, since the subjects included
are not unrelated and come from only a small number of differ-
ent families, this type of statistical analysis is in fact not fully
appropriate, as the number of independent observations is lim-
ited. The use of nonparametric tests does not overcome this
problem of nonindependent samples. However, since then we
ApoE2(Lys 146-+Gln) Associated with Familial Dysbetalipoproteinemia 1257
learned that with a new generation of statistical programs, e.g.,
Mendel and Fisher, it is possible, indeed, to study the influence
of measured alleles on quantitative traits among relatives under
different models. In this study we were not hampered by the
limited number of independent observations (families) any-
more, as we used the pedigree-based maximum likelihood
method developed by Lange et al. (46) for analyzing the effect
of the apoE2(Lysl46-.Gln) on quantitative lipoprotein traits
relevant for FD. In addition, by using the nested multi- and
univariate analysis of variance, we were also able to compare
the effect of the APOE*2(Lysl46-.Gln) allele on the expres-
sion of FD with that of the previously described APOE*3-
Leiden allele (32), in an appropriate way.
The results clearly show that the apoE2(Lysl46-eGln) vari-
ant is, like the rare apoE variants mentioned above, invariably
associated with the expression of FD, but the phenotypic expres-
sion varies to a large extent. Although gender does contribute
to the total variance in quantitative FD-related lipoprotein traits
to a certain extent, it is obvious that the APOE*2(Lysl46-eGln)
allele carrier status is more important in the expression of FD
characteristics in these families.
Using nested multivariate analysis of variance, we found
that APOE*2(Lysl46-eGln) and APOE*3-Leiden allele carri-
ers significantly differ with respect to the expression of FD
(Table IV): (a) in the APOE*2(Lysl46-{Gln) allele carriers,
the increased lipid levels occurred mainly in the VLDL fraction
rather than in the IDL fraction, whereas in the apoE3-Leiden
subjects the increased plasma cholesterol is due more specifi-
cally to an elevated IDL level, like that observed in "classical"
FD patients with homozygosity for the APOE*2(Arg158-Cys)
allele (48). In addition, in the APOE*2(Lysl46-lGln) allele
carriers the VLDL + IDL lipoprotein fraction is relatively en-
riched in triglycerides as illustrated by the much lower ratio
of cholesterol to triglycerides in this fraction (Table IV); (b)
separate quantitative isoelectric focusing experiments of plasma
and the different lipoprotein fractions, showed that in the
APOE*3-Leiden allele carriers the apoE3-Leiden variant is
much more abundant than the common apoE protein. This pre-
dominance is most prominent in the VLDL and IDL density
range (32) and is due to an enhanced-binding affinity of the
apoE3-Leiden protein to the VLDL lipoprotein fraction (49).
Such a selective accumulation of the mutant apoE protein on
the VLDL and IDL lipoprotein particles has also been reported
for the apoE3(Cysll2-'Arg;Argl42--'Cys) variant (50). In
contrast, in the APOE*2(Lysl46-sGln) allele carriers, a pre-
dominance of the mutant apoE protein relative to its normal
apoE counterpart was not observed (26, 27).
APPENDIX
Data of all family members including probands
These differences strongly suggest different metabolic de-
fects underlying the dominant mode of inheritance of FD for
the rare apoE2(Lysl46-+Gln) and apoE3-Leiden variants. In
the case of apoE3-Leiden subjects, the predominance of apoE3-
Leiden converts the d < 1.019 g/ml lipoprotein fraction into
"apparent" homozygosity for the binding-defective apoE3-
Leiden protein. This apparent homozygosity will, possibly in
combination with a modulating effect of the abundant apoE3-
Leiden protein on the conformation of the remaining normal
apoE, lead to an impaired receptor-mediated clearance of these
lipoprotein particles from the circulation. Such a mechanism is
also supported by the observation that in the apoE3-Leiden
family, the APOE*2(Argl58--Cys) allele as counter allele re-
sults in a more severe FD phenotype, whereas the
APOE*4(Cys 12-.Arg) allele acts in the opposite way (32).
For the apoE2(Lysl46-+Gln) variant, this mechanism does
not hold true. It has been suggested by Mahley and co-workers
(51) that the loss of any positively charged amino acid residue
within the receptor-binding domain of apoE, between amino acid
residue 131 and 150, affects the binding of apoE to the receptor
by reducing the ionic interaction. This interaction is probably not
easily modified by environmental factors and lipid composition of
the lipoprotein particle. As a consequence, these authors hypothe-
size that mutations in the 131-150 segment of apoE result in
"permanent" receptor-binding defects. This hypothesis is sup-
ported by experiments using apoE variants made by site-directed
mutagenesis (13). In line with this reasoning, we found that VLDL
lipoproteins, isolated from APOE*2(Lys146--Gln) allele carriers,
are also defective in binding to the LDL receptor in vitro, but
much less defective than VLDL from subjects with homozygosity
for the common APOE*2(Argl58-Cys) allele (M. Mulder and
L. Havekes, unpublished observations). It is unlikely that this
relatively little impaired binding of the apoE2(Lysl46-{Gln) pro-
tein to the receptor is the major cause of the dominant behavior
of this protein in the expression of FD. From the results presented,
we hypothesize that in the apoE2(Lysl46-+Gln) subjects, the con-
version ofVLDL into IDL is impaired. Very recently, we obtained
some evidence that this reduced VLDL into IDL conversion is
due to an impaired lipolysis of these particles by the enzyme
lipoprotein lipase (M. Mulder and L. Havekes, unpublished re-
sults). An impaired conversion into IDL would eventually lead to
a less efficient binding of these lipoproteins to the LDL receptor
in the liver, despite the presence of normal apoE protein, and
in that way, might explain the dominant behavior of the apoE2
(Lysl46-+Gln) protein in the expression of FD.
Plasma VLDL Plasma VLDL IDL LDL HDL
no. BMI' age' sex triglycerides (mmol/1) cholesterol (mmol) ratios APOE -VLDL plasma clinicalgenotypel apoE symptoms
Family proband R.L.
11-1 26.6 76 F 2.11
11-2 25.9 74 F 2.30
11-3 26.6 71 F 1.41
11-4 31.0 67 M 0.86
Illl- 20.0 45 F 1.16
111-2 27.2 46 M 3.03
111-3 21.3 40 M 2.54
111-4 20.6 38 F 1.64
111-S5 20.6 36 F 1.22
1.45 7.15 1.84 0.77
1.51 5.82 1.34 0.67
0.82 5.22 0.50 0.28
0.50 4.94 0.30 0.19
0.58 4.44 0.49 0.31
2.64 5.89 0.88 0.22
1.80 5.50 1.99 0.68
0.98 4.05 0.98 0.36
0.58 4.52 0.33 0.22
3.07 1.47 1.24 3/* + 26.4
2.39 1.42 0.87 3/* + 34.8 M
2.99 1.45 0.55 3/3
3.05 1.40 0.57 3/3
5.8
4.7
2.23 1.41 0.69 3/* + 10.5
3.26 1.53 0.36 3/3 4.7
1.72 1.11 1.05 2/* + 31.3 P;X
1.52 1.19 0.82 4/* + 12.9
2.10 1.87 0.45 3/2 4.6
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Family proband F.D.
1l1- 21.0 61 F 1.87
11-2 21.0 59 M 0.92
11-3 19.0 55 M 2.32
11-4 23.7 52 F 1.61
11-5 21.2 54 F 0.96
11-6 21.5 53 M 3.52
11-7 25.3 51 M 4.64
11-8 25.7 41 F 1.50
11-9 22.0 48 M 3.04
11-10 25.6 48 F 5.22
11-11 22.8 47 M 2.90
11-12 21.6 46 F 0.66
111-1 20.0 25 F 1.38
111-2 19.4 23 F 1.29
111-3 17.6 20 M 1.88
114 17.3 11 M 0.57
111-S5 24.3 23 M 7.73
111-6 19.8 21 F 3.46
111-7 18.1 16 M 2.23
111-8 20.9 19 M 1.68
111-9 19.5 16 M 1.15
111-10 16.5 1 1 M 0.80
1.13
0.37
1.30
0.93
0.43
2.97
3.49
0.75
2.05
4.28
1.83
0.15
0.64
0.55
1.22
0.20
6.02
2.36
1.64
1.00
0.58
0.30
5.68 1.05 0.49
5.40 0.19 0.19
6.85 1.52 0.64
6.40 0.42 0.38
5.50 0.34 0.30
4.98 1.65 0.32
6.22 2.75 0.57
4.37 0.50 0.22
8.55 2.75 0.79
5.30 1.50 0.31
7.47 1.66 0.59
4.44 0.16 0.15
6.02 0.29 0.24
6.69 0.22 0.19
3.93 0.76 0.25
3.29 0.27 0.18
9.78 5.05 0.43
5.80 1.94 0.69
5.60 0.75 0.21
3.94 0.83 0.33
4.51 0.57 0.19
4.15 0.28 0.09
2.56
3.68
3.47
4.06
3.28
1.77
1.82
2.43
3.84
2.68
3.49
2.53
3.07
3.60
1.69
1.42
3.47
2.06
3.35
1.64
2.21
2.24
1.58 0.82
1.34 0.41
1.22 0.93
1.54 0.50
1.58 0.67
1.24 0.56
1.08 0.72
1.22 0.48
1.17 1.16
0.81 0.35
1.73 0.78
1.60 0.47
2.42 0.38
2.68 0.32
1.23 0.54
1.42 0.79
0.83 0.71
1.11 0.76
1.29 0.43
1.14 0.69
1.54 0.66
1.54 0.46
3/* + 26.4 M
3/3 - 6.1
3/0 + 27.1
3/3 - 6.4
3/3 - 6.0
3/* + 26.9 M
3/' + 24.9 M;X
3/3 - 4.3
3/* + 29.8
3/3 + 9.0
3/* + 26.3 P;X
3/3 + 2.9
3/3 - 5.4
3/3 - 5.6
3/* + 16.7
3/* +/- 18.3
3/* + 39.1
3/* + 23.4
3/3 - 6.7
3/' + 18.3
3/* + 22.3
3/3 +/- 2.1
Family proband M.N.
1-1 26.2 82 M 4.62
1-2 32.0 78 F 5.57
11-1 26.1 59 M 15.59
11-2 32.0 56 F 7.11
11-3 35.2 56 M 1.60
111-1 26.7 33 M 4.26
111-2 27.8 31 M 1.93
111-3 29.0 27 F 6.48
Family proband F.V.
11-1 25.8 64 F 3.34
11-2 29.1 61 F 1.97
11-3 28.3 52 M 11.37
11-4 23.4 47 F 0.72
111-1 13.4 20 F 1.47
111-2 20.6 18 M 2.12
3.84
4.25
13.78
4.91 1.32 0.28
8.96 3.45 0.94
20.83 16.24 0.59
6.07 6.56 4.20 0.50
0.97 4.87 0.50 0.28
3.50 7.20 3.63 0.35
1.45 5.85 0.64 0.27
5.15 6.67 3.77 0.55
2.19
1.23
8.71
0.23
1.00
1.57
6.92 1.34 0.92
7.05 0.66 0.54
9.77 5.89 0.51
5.77 0.15 0.16
4.49 0.69 0.23
4.22 0.57 0.19
2.50 0.81 0.35
3.35 1.22 0.79
2.99 1.01 1.08
0.80
3.11
2.16
3.98
1.20
1.06 0.66
0.98 0.49
1.06 0.93
0.96 0.47
1.15 0.67
3.20 1.46 0.68
4.48 1.37 0.61
2.12 1.25 0.56
3.34 2.12 0.43
1.81 1.76 0.63
2.04 1.42 0.36
3/3 + 5.6
3/' + 52.6 X
3/' + 75.2 X
3/* + 33.1 P;X;M
3/3 - 4.8 M
3/' + 34.6
3/3 _ 4.5
3/* + 36.2
3/3 + 6.2
3/3 - 6.6
3/* + 50.2 P;X;M
4/3 _ 3.4
3/' + 19.7
4/3 _ 3.9
Family proband R.v.D.
111-1 23.6 60 F 3.68
111-2 24.5 55 M 3.52
111-3 25.7 59 M 3.87
111-4 21.5 55 F 1.31
111-5 20.1 53 F 3.27
IK6 23.4 57 M 1.82
111-7 23.8 52 F 1.83
111-8 23.1 43 M 5.35
111-9 20.6 44 F 1.05
111-10 23.1 70 F 1.44
111-11 21.2 73 M 1.62
111-12 30.5 67 F 1.67
2.24 9.74 3.44 1.27
2.45 6.75 1.50 0.27
2.96 7.24 2.56 0.38
0.72 6.93 0.34 0.19
2.33 7.02 2.57 0.68
1.35 5.76 0.68 0.24
1.19 7.90 0.70 0.38
4.34 8.31 4.05 0.69
0.34 4.30 0.32 0.25
0.78 6.11 0.82 0.57
1.22 4.78 0.58 0.11
0.98 5.38 0.83 0.56
3.88
3.71
3.48
5.12
2.63
3.70
5.59
2.57
2.13
3.35
2.77
2.75
1.15 1.28
1.27 0.50
0.82 0.76
1.28 0.40
1.14 0.99
1.14 0.51
1.23 0.59
1.00 0.89
1.60 0.54
1.37 0.97
1.32 0.43
1.24 0.83
4/* + 43.3 P;M
4/3 - 7.4
3/* + 34.4 M
3/3 - 4.0
3/* + 34.5
4/3 5.9
4/4 3.5
4/' + 30.9
3/2 5.1
3/' +/ 31.6
3/3 - 7.1
3/' + 37.0
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Plasma VLDL Plasma VLDL IDL LDL HDL
no. BMI' ages sex triglycerides (mmoOA) cholesterol (mmoOA) ratiol APOE O-VLDL plasma diical
genotype1 apoE symptoms
111-12 27.1 71 M 1.44
111-14 27.7 62 F 2.12
111-15 26.5 61 M 1.45
111-16 22.5 59 M 1.09
111-17 25.0 56 M 1.86
111-18 34.2 54 F 1.58
111-19 33.4 51 F 2.87
111-20 24.6 50 M 1.81
111-21 24.7 47 M 1.91
111-22 31.2 46 F 1.02
111-23 26.6 44 M 3.05
111-24 28.3 47 F 0.65
111-25 28.6 42 M 2.33
24.8 62 M 2.54
26.3 61 F 3.21
25.3 43 M 2.37
21.7 41 F 1.06
20.6 31 F 0.94
21.6 29 M 6.48
20.4 24 F 1.35
24.8 33 F 3.56
25.7 31 M 1.14
23.1 31 F 1.13
20.2 29 F 1.57
21.0 18 F 1.90
20.1 16 M 1.75
24.8 44 F 1.16
22.5 39 F 1.33
21.2 31 M 2.13
29.2 37 M 4.62
22.5 20 F 0.47
30.8 20 F 1.33
24.3 26 F 0.94
23.9 19 F 0.94
22.1 19 M 1.26
19.8 36 F 3.13
17.8 14 M 0.63
0.89 5.06 0.36 0.19
1.45 8.40 0.81 0.47
0.76 7.92 0.47 0.28
0.52 6.78 0.39 0.30
1.19 6.54 0.81 0.26
0.89 7.08 0.66 0.23
1.87 7.35 1.20 0.47
1.07 6.63 0.70 0.26
1.00 9.36 1.96 0.84
0.49 5.65 0.40 0.10
1.99 9.25 2.66 0.51
0.10 7.27 0.20 0.21
1.52 9.52 1.10 0.33
1.73 6.21 1.57 0.65
2.19 6.63 1.42 0.60
1.63 5.81 1.60 0.49
0.41 6.29 0.33 0.21
0.33 4.91 0.25 0.25
5.11 7.19 3.91 0.55
0.57 5.10 0.31 0.14
2.15 6.14 1.83 0.57
0.73 5.29 0.33 0.19
0.59 4.57 0.35 0.18
1.07 5.26 0.87 0.35
1.25 4.85 1.04 0.35
1.26 4.99 1.63 0.46
0.66 4.86 0.46 0.24
0.98 3.61 0.70 0.22
1.39 4.88 1.11 0.42
3.72 7.78 3.46 0.25
0.09 4.95 0.18 0.13
0.66 7.92 0.46 0.21
0.21 6.32 0.26 0.25
0.58 5.52 0.49 0.15
0.76 4.81 0.49 0.21
2.25 6.69 2.12 0.72
0.24 4.21 0.31 0.17
3.10 1.41 0.38
5.79 1.33 0.60
5.84 1.33 0.52
4.79 1.30 0.63
4.41 1.06 0.58
4.82 1.37 0.56
4.56 1.12 0.58
4.34 1.33 0.53
5.26 1.30 1.47
3.64 1.51 0.49
4.60 1.48 1.04
5.13 1.73 0.63
6.93 1.16 0.61
2.89 1.10 0.87
3.12 1.49 0.63
2.44 1.28 0.88
3.46 2.29 0.51
3.17 1.24 0.53
1.84 0.89 0.69
3.13 1.42 0.33
2.11 1.63 0.67
3.75 1.02 0.46
2.42 1.62 0.47
2.60 1.44 0.78
2.17 1.29 0.73
1.79 1.11 1.19
2.92 1.24 0.60
1.36 1.33 0.69
2.34 1.01 0.72
2.88 1.19 0.80
2.83 1.81 0.66
5.41 1.84 0.50
3.90 1.91 0.54
3.48
2.64
2.65
1.98
1.40 0.68
1.47 0.56
1.20 0.91
1.75 0.76
Family proband F.H.
11-i 25.7 80 F 1.05
11-2 24.7 73 M 1.29
11-3 20.3 72 F 2.77
11-4 24.1 70 M 2.29
111-i 21.2 42 F 0.97
111-2 20.6 38 F 1.91
111-3 21.0 39 M 1.38
111-4 25.1 36 M 1.78
0.30 7.07 0.24 0.21
0.69 6.22 0.25 0.15
1.98 9.49 3.09 0.79
1.76 5.53 1.26 0.40
0.39 4.47 0.23 0.14
1.13 6.33 0.56 0.37
0.94 6.03 0.42 0.15
1.13 7.77 1.08 0.56
4.88 1.74 0.43
3.95 1.87 0.31
4.54 1.07 1.40
2.63 1.24 0.72
2.93 1.17 0.38
3.91 1.49 0.49
3.85 1.61 0.41
5.02 1.11 0.92
3/3 - 5.9
313 - 5.0
3/* + 33.7
3/* + 25.8
3/3 - 1.7
313 +/- 4.1
313 - 4.3
3/* +/- 24.8
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M
M
111-26
111-27
111-28
111-29
IV-01
IV-02
IV-03
IV04
IV-5
IV06
IV07
IV08
IV09
IV-10
IV-1I
IV-12
IV-13
IV-14
IV-15
IV-16
IV-17
IV-18
IV-1 9
IV-20
3/3
4/3
4/4
4/4
4/4
4/4
4/4
4/4
4/*
3/3
4/*
3/3
4/4
3/*
4/3
3/*
3/3
4/4
4/*
4/3
3/*
3/3
4/3
4/*
4/*
2/*
3/3
3/*
3/3
3/*
4/3
4/3
4/3
4/3
4/3
4/*
3/*
4.8
6.7
1.9
1.7
2.9
3.2
4.1
5.2
31.9
4.6
29.7
2.4
5.5
18.5
7.7
26.4
4.6
2.3
34.1
3.0
24.1
4.5
4.4
16.8
22.9
29.5
5.9
10.6
16.8
44.4
2.5
6.2
2.2
2.0
2.2
29.3
25.4
M
M
P;M
Family number corr ing with that in pedigrees of Figure 2; 5BMI: body mass index in weight/height2 (kg/sni); 'Persons age at the timepoint of bloodsampling in years.
Vatio: (VLDL+IDL)-cholesterol/plasma triglycerides; plasma apoE concentrations are given in mg/dl. APOE genotyping; 2, 3, 4 represent common alleles:
APOE*2(Arg158-Cys), APOE*3, APOE*4(Cys12-Arg), respectively; *, represents APOE*2(Lys146.Gln) allele. #-VLDL: presence (+) or absence (-) of O-VLDL as
characterized by agarose electrophoresis. $Remarks: X: xanthomas present at first visit (palmar or tubero-eruptive type); M: medication, individual is taken lipid lowering
drug; P: proband of respective family.
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